Luther Y, Bantis C, Ivens K, Fehsel K, Kolb-Bachhofen V, Heering P
Department of Nephrology and Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany.
Kidney Blood Press Res. 2003;26(5-6):333-7. doi: 10.1159/000073939.
BACKGROUND/AIMS: We analyzed the influence of angiotensin-converting enzyme (ACE) I/D, angiotensinogen (AGT) M235T and angiotensin-II-type-1 receptor (AT1R) A1166C genetic polymorphisms on the clinical course of focal segmental glomerulosclerosis (FSGS).
This study consisted of 71 patients with nephrotic syndrome due to biopsy proven FSGS and 100 healthy controls. According to the slope of the reciprocal serum creatinine (1/Cr, >or= or <-0.1 dl x mg(-1) x year(-1)) patients were classified into group A (slow progressors, n = 50) and group B (fast progressors, n = 21). Genotyping was performed using polymerase chain reaction (PCR).
There were no relevant differences in the allele frequencies of the investigated polymorphisms between patients with FSGS and controls. Patients carrying the T- allele of the AGT polymorphism required a larger number of antihypertensive agents (MM: 1.35 +/- 1.0 vs. MT/TT: 2.0 +/- 1.2, p < 0.05). The ACE-ID/DD genotypes were more frequently found in patients with fast progression (group A: II: 38.0%, ID/DD: 62.0% vs. group B: II: 14.3%, ID/DD: 85.7%, p < 0.05). The AT1R-A1166C polymorphism was not associated with any of the parameters studied.
The course of FSGS is in part genetically determined by polymorphisms of the renin-angiotensin-system. The ACE-I/D polymorphism was shown to be a risk factor of progression of renal disease and the AGT-M235T polymorphism was associated with the severity of arterial hypertension.
背景/目的:我们分析了血管紧张素转换酶(ACE)I/D、血管紧张素原(AGT)M235T和血管紧张素II 1型受体(AT1R)A1166C基因多态性对局灶节段性肾小球硬化(FSGS)临床病程的影响。
本研究包括71例经活检证实为FSGS的肾病综合征患者和100例健康对照。根据血清肌酐倒数的斜率(1/Cr,≥或≤-0.1 dl×mg-1×年-1),患者被分为A组(进展缓慢者,n = 50)和B组(进展快速者,n = 21)。采用聚合酶链反应(PCR)进行基因分型。
FSGS患者与对照组之间,所研究多态性的等位基因频率无显著差异。携带AGT多态性T等位基因的患者需要更多种类的抗高血压药物(MM:1.35±1.0 vs. MT/TT:2.0±1.2,p < 0.05)。ACE-I/D/DD基因型在进展快速的患者中更为常见(A组:II:38.0%,ID/DD:62.0% vs. B组:II:14.3%,ID/DD:85.7%,p < 0.05)。AT1R-A1166C多态性与所研究的任何参数均无关联。
FSGS的病程部分由肾素-血管紧张素系统的多态性决定。ACE-I/D多态性被证明是肾脏疾病进展的危险因素,而AGT-M235T多态性与动脉高血压的严重程度相关。